Phase 1 trial of olaratumab monotherapy and in combination with chemotherapy in pediatric patients with relapsed/refractory solid and central nervous system tumors

Olaratumab is a monoclonal antibody that specifically binds to platelet‐derived growth factor receptor alpha (PDGFRα) and blocks receptor activation. We conducted a phase 1 trial to evaluate the safety of olaratumab and determine a recommended dose in combination with three different chemotherapy re...

Descripción completa

Detalles Bibliográficos
Autores principales: Mascarenhas, Leo, Ogawa, Chitose, Laetsch, Theodore W., Weigel, Brenda J., Bishop, Michael W., Krystal, Julie, Borinstein, Scott C., Slotkin, Emily K., Muscal, Jodi A., Hingorani, Pooja, Levy, Donna E., Mo, Gary, Shahir, Ashwin, Wright, Jennifer, DuBois, Steven G.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Clinical Cancer Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7897905/
https://www.ncbi.nlm.nih.gov/pubmed/33474828
http://dx.doi.org/10.1002/cam4.3658

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7897905/
https://www.ncbi.nlm.nih.gov/pubmed/33474828
http://dx.doi.org/10.1002/cam4.3658

Ejemplares similares